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Currently, the vast majority of these patients with mild strokes does not receive an immediate vessel imaging 
with either computed tomographic or magnetic resonance 
angiography. However, acute ischemic stroke patients with 
low National Institutes of Health Stroke Scale (NIHSS) who 
harbor a large vessel occlusion (LVO) decline at a 20% to 
40% rate1,2 and have underappreciated impairments related 
to their relatively mild strokes.3 Similarly, LVO patients pre-
senting with a transient ischemic attack are under increased 
risk of clinical deterioration.4,5 Experience with mechanical 
thrombectomy (MT) in the LVO mild stroke target popula-
tion is limited. Among the recent endovascular trials dem-
onstrating efficacy, baseline stroke severity did not modify 
treatment effect.6 However, only 14 of 1766 patients in the 
recent randomized controlled trials7–13 had a low baseline 
NIHSS (0–5). Only few nonrandomized studies comparing 
immediate MT (IMT) with initial best medical management 
(BMM) have been published so far with data indicating no 
benefit of IMT,14,15 all the way up to 23% to 43% difference 
in good outcome favoring IMT.1,16,17 Hence, the efficacy and 
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Background and Purpose—We aimed to describe the safety and efficacy of immediate mechanical thrombectomy (MT) 
in patients with large vessel occlusions and low National Institutes of Health Stroke Scale (NIHSS) versus best medical 
management.
Methods—Patients from prospectively collected databases of 6 international comprehensive stroke centers with large vessel 
occlusions (distal intracranial internal carotid, middle cerebral artery-M1 and M2 segments, or basilar artery with or 
without tandem occlusions) and NIHSS 0 to 5 were identified and divided into 2 groups for analysis: immediate MT or 
initial best medical management which included rescue MT after neurological deterioration (best medical management-
MT). Uni- and multivariate analyses and patient-level matching for age, baseline NIHSS, and occlusion site were 
performed to compare baseline and outcome variables across the 2 groups. The primary outcome was defined as good 
outcome (modified Rankin Scale score, 0–2) at day 90. Safety outcome was symptomatic intracranial hemorrhage as 
defined by the ECASS (European Cooperative Acute Stroke Study) II and mortality at day 90.
Results—Compared with best medical management-MT (n=220), patients with immediate MT (n=80) were younger 
(65.3±13.5 versus 69.5±14.1; P=0.021), had more often atrial fibrillation (44.8% versus 28.2%; P=0.012), higher baseline 
NIHSS (4, 0–5 versus 3, 0–5; P=0.005), higher Alberta Stroke Program Early CT Score (10, 7–10 versus 10, 5–10; 
P=0.023), more middle cerebral artery-M1, and less middle cerebral artery-M2 (41.3% versus 21.9% and 28.8% versus 
49.3%; P=0.016) occlusions. The adjusted odds ratio for good outcome was 3.1 (95% CI, 1.4–6.9) favoring immediate 
MT. In the matched analysis, there was a 14.4% absolute difference in good outcome (84.4% versus 70.1%; P=0.03) at 
day 90 favoring immediate MT. There were no safety concerns.
Conclusions—Our retrospective, pilot analysis suggests that immediate thrombectomy in large vessel occlusions patients 
with low NIHSS on presentation may be safe and has the potential to result in improved outcomes. Randomized clinical 
trials are warranted to establish the optimal management for this patient population.   (Stroke. 2018;49:2391-2397. DOI: 
10.1161/STROKEAHA.118.021106.)
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safety of IMT versus BMM (including intravenous recom-
binant tissue-type plasminogen activator if applicable and 
rescue MT in case of clinical deterioration) for patients with 
low NIHSS and LVOs have not been established. Here, we 
present a large retrospective multicenter analysis of prospec-
tively collected data on patients with mild stroke harboring 
an LVO from 6 international comprehensive stroke centers.
Methods
The data that support the findings of this study are available from the 
corresponding author on reasonable request. Prospectively run local 
acute ischemic stroke databases (Heidelberg University Hospital, 
Munich University Hospital, Osnabrück Hospital, Massachusetts 
General Hospital, University of California San Francisco Hospital, 
and Grady Memorial Hospital) were searched for patients with (1) 
baseline NIHSS 0 to 5, (2) proven (by computed tomographic an-
giography or magnetic resonance angiography) LVO including in-
tracranial internal carotid, middle cerebral artery (MCA)-M1, and 
MCA-M2 with or without tandem occlusions or anterior cerebral 
artery or basilar occlusion, and (3) available 3-month outcome data. 
Data were retrieved from routine clinical documentation. However, 
in contrast to what is typically done in prospective clinical trials, 
no formal audits or site monitoring was performed. Patients with 
isolated cervical intracranial internal carotid occlusions (and patent 
intracranial vessels) were excluded from analysis. The data col-
lection period differed across the different centers but included all 
consecutive patients fulfilling the above criteria with the following 
distribution: Heidelberg University Hospital: 66 of 2391 (2.8%) 
patients from 2005 to 2016, Munich University Hospital: 16 of 
346 (4.6%) patients from 2015 to 2016, Osnabrück Hospital: 75 
of 1040 (7.2%) patients from 2012 to 2016, STOPStroke Registry 
(Massachusetts General Hospital/University of California San 
Francisco Hospital): 88 of 741 (11.9%) patients from 2003 to 2005, 
and Grady Memorial Hospital: 55 of 450 (12.2%) patients from 
2014 to 2016. In all centers, treatment decisions were made by the 
treating physician.
We retrieved relevant clinical baseline characteristics, radi-
ological findings, as well procedural aspects and outcome data. 
Recanalization was assessed with the modified Thrombolysis in 
Cerebral Infarction scale, and successful recanalization was defined 
as modified Thrombolysis in Cerebral Infarction ≥2b. The primary 
outcome was the rate of good functional outcomes as defined as mod-
ified Rankin Scale (mRS) 0 to 2 at 90 days and was obtained through 
outpatient assessments or a standardized interview by an unblinded 
investigator and, if those were not possible, through detailed reha-
bilitation reports containing a full description of the clinical deficit, 
Barthel-Index, and social medicine data at discharge (5% of patients, 
ie, 15 of 300, all German patients).
Secondary outcomes were the rates of excellent outcome (mRS, 
0–1) at day 90 and a mRS shift analysis at day 90. Exploratory 
analyzes were performed to assess treatment benefit using alterna-
tive mRS shift analysis methods (method B: 0–2, 3, 4, 5–6; method 
C: 0–1, 2, 3, 4, 5–6; method D: 0–1, 2, 3, 4–6). Safety outcome 
was symptomatic intracranial hemorrhage (sICH) as defined by the 
ECASS (European Cooperative Acute Stroke Study) II18 and mor-
tality at day 90.
Patients were divided into 2 groups: patients who received 
IMT or initial BMM including intravenous thrombolysis if appli-
cable and rescue MT after neurological deterioration (BMM-MT) 
as determined by the local clinical team. For all procedures, local 
standard operating procedures and local guidelines were followed. 
All patients were treated either on local stroke units or neurocritical 
care units. In all MT procedures, an approved stent retriever and as-
piration catheter were used.
Local ethics approval was obtained from each participating center 
for the local databases, and only pseudonymized data without per-
sonal information were entered in the combined database for anal-
ysis. The local ethics boards waived the need for patient consent for 
the purposes of this retrospective analysis.
Matching Methodology
Patients were first categorized into 6 categories according to occlu-
sion site: intracranial internal carotid artery, MCA-M1, MCA-M2, 
anterior cerebral artery, tandem, and basilar artery. For each group, a 
matching method based on weighted Euclidean distances was used to 
obtain a pair of subjects considered to be the nearest neighbors in a 
bidimensional space of age and baseline NIHSS score, as previously 
described.19 Because of collinearity of NIHSS and Alberta Stroke 
Program Early CT Score (ASPECTS) and the aim to avoid over-
matching, we decided for NIHSS and not ASPECTS to be included 
in the matching procedure. Moreover, the difference between groups 
in NIHSS was greater in the overall cohort than for ASPECTS. The 
distance between each IMT-BMM-MT pair was computed using 
the %FIND_NEIGHBORS Macro in SAS University Edition (SAS 
Institute, Cary, NC). Each IMT patient was matched with nearest 
BMM-MT patient (having the smallest Euclidian distance). After 
matching, the distribution of Euclidian distances was studied to iden-
tify outliers, and a threshold was determined as follows: threshold=Q
75+1.5*(Q75−Q25), where Q25 and Q75 are, respectively, the 25th 
and 75th percentiles. Pairs with distances greater than the threshold 
were considered extreme values at the tail of the distribution and 
eliminated from further consideration.
Statistical Analysis
Nominal variables are presented as frequencies, ordinal values as 
medians with min–max distribution, and continuous variables as 
mean±SD. For the whole cohort, all comparative analyses were 
done with the Fisher exact-test, the χ2, Mann-Whitney, or Kruskal-
Wallis resp. T test where appropriate and a P<0.05 was considered 
as significant. To identify independent predictors of good outcome, 
we used a stepwise forward logistic regression model including all 
variables with P≤0.1 after univariate analysis (age, baseline mRS, 
hypertension, history of smoking, recombinant tissue-type plasmin-
ogen activator use, onset to treatment time, and IMT). Odds ratios 
(OR) are presented with 95% CIs. For the matched cohort analysis, 
mRS shift analysis and modifications of it were performed by Van 
Elteren test and ordinal regression for OR. Statistical analysis was 
performed using IBM SPSS Statistics 23 (IBM-Armonk, NY) and 
SAS University Edition (SAS Institute).
Results
Overall Cohort
A total of 300 patients were included. Mean age was 
68.3±14 years, and 53.7% of patients were men. Except for 
Massachusetts General Hospital/University of California 
San Francisco Hospital (STOPStroke Registry dataset), 
all other centers contributed IMT patients to this analysis 
within a range of 19% to 49% of all contributed patients. 
Patients had a typical distribution of cardiovascular risk fac-
tors (Table 1). Twenty (6.7%) patients with a preexisting 
baseline disability (mRS>2) were included. As compared 
with BMM-MT patients (n=220), IMT patients (n=80) 
were younger (65.3%±13.5 versus 69.5±14.1; P=0.021), 
more often had atrial fibrillation (44.8% versus 28.2%; 
P=0.012), and had higher baseline NIHSS (4, 0–5 versus 
3, 0–5; P=0.005), as well as more MCA-M1 (41.3% versus 
21.9%) and less MCA-M2 (28.8% versus 49.3%; P=0.016) 
occlusions, and had higher baseline ASPECTS scores (10, 
7–10 versus 10, 5–10; P=0.023). The frequency of intra-
venous recombinant tissue-type plasminogen activator use 
was similar in both groups (47.5% versus 51.8%; P=0.39). 
Twenty-five (11.3%) patients in the BMM-MT group re-
ceived rescue MT. The most prominent MT maneuver was 
stent retrievers on first pass in both groups (IMT 86% versus 
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Table 1.  Univariate Analysis and Distribution of Patient Characteristics, Lab Values, Procedure Times, and Imaging Data in Patients 
With Favorable and Unfavorable Outcomes
Patient Characteristics All Patients (n=300) IMT (n=80) BMM-MT (n=220) P Value
Baseline clinical characteristics
  Age, y, mean±SD 68.3±14 65.3±13.5 69.5±14.1 0.02*†
  Male, n (%) 161 (53.7) 44 (55) 117 (53.2) 0.79‡
  Hypertension, n (%) 215 (71.7) 56 (70) 159 (72.3) 0.77‡
  Diabetes mellitus, n (%) 49 (16.3) 13 (16.3) 36 (16.4%) 1.0‡
  Atrial fibrillation, n (%) 97 (32.3) 35 (43.8) 62 (28.2) 0.012†‡
  Hypercholesterolemia, n (%) 111 (37) 29 (36.3) 82 (37.3) 0.89‡
  History of smoking, n (%) 66 (22) 16 (20) 50 (22.7) 0.75‡
  Oral anticoagulation, n (%) 42 (17.9) 9 (13) 33 (20) 0.26‡
  Baseline mRS, median (min–max) 0 (0–4) 0 (0–4) 0 (0–4) 0.88§
  Baseline mRS >2 (%) 20 (6.6) 4 (5) 16 (7.3) NA
  Baseline NIHSS, median (min–max) 3 (0–5) 4 (0–5) 3 (0–5) 0.008†§
  MAP on admission in mm Hg, mean±SD 114±19 114±19 114±19 0.82*
Radiological findings, procedural aspects, and outcome measures
  ASPECTS, median (min–max) 10 (5–10) 10 (7–10) 10 (5–10) 0.023†§
  Occlusion site Distal ICA/carotid 
T, n (%)
27 (9) 7 (8.8) 22 (9.1) 0.016†‖
Tandem occlusion, 
n (%)
36 (12) 10 (12.5) 26 (11.9)
M1, n (%) 81 (27.1%) 33 (41.3) 48 (21.9)
M2, n (%) 131 (43.8) 23 (28.8) 108 (49.3)
ACA, n (%) 3 (1) 1 (1.3) 2 (0.9)
Basilar artery, (%) 21 (7) 6 (7.5) 15 (6.8)
  Treatment year, median (min–max) 2012 (02–16) 2015 (12–16) 2010 (02–16) 0.001†§
  Intravenous rt-PA, n (%) 152 (50.7) 38 (47.5) 114 (51.8) 0.51‡
  Rescue MT, n (%) NA NA 25/220 (11.3) NA
  Onset to treatment time, min, mean±SD 403±520 319±391 433±557 0.01*
  Door to needle time, min, mean±SD 46±33 37±23 47±35 0.15*
  Door to groin puncture time, min, mean±SD 169±232 93±75 409±367 0.001*†
  Recanalization (TICI 2b–3), (%) 93/105 (88.6) 70 (87.5) 23/25 (92) 0.72‡
  sICH, n (%) 7 (2.3) 4 (5) 3 (1.4) 0.08‡
  Excellent outcome (mRS, 0–1), n (%) 173 (57.7) 49 (61.3) 124 (56.4) 0.51‡
  Good outcome (mRS, 0–2), n (%) 222 (74) 68 (85) 154 (70) 0.011†‡
  Good outcome including back to baseline 
mRS, n (%)
233 (77.7) 69 (86.3) 164 (74.5) 0.041†‡
  Mortality, n (%) 23 (7.7) 3 (3.8) 20 (9.1) 0.14‡
Onset to treatment time: treatment is defined as start rt-PA or groin puncture or best medical management if no 
recanalization therapy was offered. ACA indicates anterior cerebral artery; ASPECTS, Alberta Stroke Program Early CT Score; 
BMM, best medical management; ICA, intracranial internal carotid; IMT, immediate mechanical thrombectomy; MAP, mean 
arterial pressure; mRS, modified Rankin Scale; MT, mechanical thrombectomy; NA, not applicable; NIHSS, National Institutes 
of Health Stroke Scale; rt-PA, recombinant tissue-type plasminogen activator; sICH, symptomatic intracranial hemorrhage; and 
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rescue MT 88%), and the rest of the patients was treated 
with aspiration catheters on first pass or throughout the pro-
cedure. Reperfusion rates were similarly high in IMT versus 
rescue-MT patients (87.5% versus 92%; P=0.72). The MT 
procedure was performed in general anesthesia in around 
half the cases in both groups (IMT 55% versus rescue MT 
48%), and the rest of the patients were treated in conscious 
sedation or monitored anesthesia care. Onset to treatment 
time and door to needle time showed a trend towards being 
shorter in IMT patients, and door to arterial puncture time 
was per definition much shorter in IMT than rescue MT 
patients (89±72 versus 322±340 minutes; P<0.001). Rates 
of sICH were low in both groups but were numerically lower 
in BMM-MT patients (5% versus 1.4%; P=0.26). Rates of 
good outcomes as well as the chances of returning to base-
line mRS were significantly higher in IMT patients (85% 
versus 70%, P=0.011 and 86.3% versus 74.5%, P=0.041). 
There were trends, but no significant differences in the rates 
of 90-day excellent outcome (61.3% versus 56.5%; P=0.18) 
or mortality (3.2% versus 8.3%; P=0.15) in IMT versus 
BMM-MT patients. Analyzing only patients who received 
intravenous thrombolysis (n=152), the difference in rates of 
good outcomes was numerically greater than in the whole 
cohort (IMT 81.6% versus BMM-MT 64.9%; P=0.068), 
but because of the lower sample size, this was not statis-
tically significant. After excluding patients with basilar ar-
tery occlusion from the analysis, we found the difference 
in the primary end point remained significant (90-day mRS 
0–2: IMT 83.8% versus BMM 70.1%; P=0.021). Younger 
age (66.4±13.7 versus 73.8±13.2; P<0.001), lower baseline 
mRS (0, 0–2 versus 0, 0–4; P<0.001), IMT (84.6% versus 
69.4%; P=0.011), and absence of hypertension (68.5% 
versus 80.8%; P=0.041) were the only factors significantly 
associated with good outcome on univariate analysis in the 
whole cohort. However, only IMT (OR, 3.1; 95% CI [1.4–
6.9]) and baseline mRS (OR, 0.31; 95% CI [0.21–0.44]) 
were identified as independent predictors of good outcome 
on multivariate analysis. Notably, separating the BMM-MT 
group into those with pure medical management (n=195) 
and those with rescue MT (n=25), we found that patients 
with rescue MT had the lowest rates of good outcome 
(54.5% for rescue-MT versus 71.7% for BMM alone versus 
85% for IMT; P=0.007)
Matched Cohort
The matching algorithm generated 77 pairs of IMT-BMM-MT 
patients, of which 2 had an Euclidian distance higher than the 
preset threshold and thus were excluded from further consid-
eration. Baseline characteristics were well balanced between 
groups except for higher rates of atrial fibrillation in the IMT 
group (45.5% versus 28.6%; P=0.03; Table 2) and baseline 
ASPECTS (10 versus 9; P=0.002; Table 2). However, this 
imbalance in ASPECTS between groups was not reflected in 
an association of ASPECTS with good outcome (10 [9–10] 
versus 10 [9–10]; P=0.09).
IMT patients had significantly higher rates of good out-
comes (84.4% versus 70.1%; P=0.03; Figure). Excellent 
outcome was not significantly different (61% versus 53.2%; 
P=0.33). Rates of sICH were numerically higher in IMT (5.2% 
versus 2.6%; P=0.37) but were not significantly different. 
Mortality was low in both groups (3.9% versus 5.2%; P=0.83).
Table 3 displays different options of 90-day mRS shift 
analyses. There was a significant shift favoring the IMT group 
when scores 0, 1, and 2 as well as 5 and 6 were aggregated 
(option B, OR, 2.29; 95% CI [1.05–4.98]; P=0.03). Two other 
modified analysis showed a trend in mRS shift favoring IMT 
(options C and D). The classic shift analysis, however, did not 
show a significant shift favoring the IMT group (option A, 
OR, 1.34; 95% CI [0.76–2.35]; P=0.32).
Table 2. Matched Analysis for Both Cohorts
Patient Characteristics IMT (n=77)
BMM-MT 
(n=77) P Value
Age, y* (median [IQR]) 68.5 [58–75] 69.5 [63–77] 0.68†
Baseline NIHSS* (median 
[IQR])
3.5 [3–5] 4 [4–5] 0.74†
Gender (male), n (%) 42 (54.5) 45 (58.4) 0.63‡
Hypertension, n (%) 54 (70.1) 55 (71.4) 0.86‡
Dyslipidemia, n (%) 28 (36.4) 30 (39.0) 0.74‡
Diabetes mellitus, n (%) 12 (15.6) 13 (16.9) 0.83‡
Atrial fibrillation, n (%) 35 (45.5) 22 (28.6) 0.03‡§
Smoking, n (%) 14 (18.2) 23 (20.8) 0.69‡
Baseline mRS   0.77†
  0 65 (84.4) 58 (84.1)  
  1 7 (9.1) 9 (13)  
  2 5 (6.5) 2 (2.9)  
Occlusion site*   1.00‡
  ICA-T 7 (9.1) 7 (9.1)  
  Tandem 9 (11.7) 9 (11.7)  
  M1 32 (41.6) 32 (41.6)  
  M2 23 (29.9) 23 (29.9)  
  Basilar 6 (7.8) 6 (7.8)  
ASPECTS, median[IQR] 10 [9–10] 9 [8.5–10] 0.002†§
MAP, mm Hg median [IQR] 115[108–128] 118[104–146] 0.35†
IV t-PA, n (%) 36 (46.8) 42 (54.5) 0.33‡
sICH, n (%) 4 (5.2) 2 (2.6) 0.41‖
Excellent outcome (mRS, 
0–1), n (%)
47 (61.0) 41 (53.2) 0.33‡
Good outcome (mRS, 0–2), 
n (%)
65 (84.4) 54 (70.1) 0.03‡§
Mortality, n (%) 3 (3.9) 4 (5.2) 0.73‡
ASPECTS indicates Alberta Stroke Program Early CT Score; BMM, best 
medical management; ICA, intracranial internal carotid; IMT, immediate 
mechanical thrombectomy; IQR, interquartile range; IV-tPA, intravenous tissue-
type plasminogen activator; MAP, mean arterial pressure; mRS, modified 
Rankin Scale; MT, mechanical thrombectomy; NIHSS, National Institutes of 
Health Stroke Scale; and sICH, symptomatic intracranial hemorrhage.
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Discussion
In this large multicentric study of patients with versus without 
IMT, we observed that IMT was an independent predictor 
of good outcome (OR, 3.1; 95% CI [1.4–6.9]) with an abso-
lute difference of 15%, suggesting that successful early MT 
improves functional independence. This finding was further 
corroborated by our matched analysis adjusting for age, base-
line NIHSS, and occlusion site (absolute difference in good 
outcome: 14.4%; 84.4% versus 70.1%; P=0.03). In addition, 
we could show in an exploratory analysis that a modified shift 
analyses on the mRS within the matched cohort also signifi-
cantly favored IMT.
Previous studies of smaller single-center and multicenter 
cohorts reported ambiguous findings in regards to MT in LVO 
patients with low NIHSS on presentation. Pfaff et al20 have 
shown that MT in LVO patients (n=33) with NIHSS ≤8 can 
be performed safely (sICH, 6%) and with reasonable rates of 
good outcome (90-day mRS, 0–2; 63.6%) even in longer time 
windows (median onset to arterial puncture of 320 minutes). 
Another German single-center report including 41 patients 
with M1 occlusions and NIHSS 0 to 5 described 4.8% sICH and 
a 75% rate of good outcome after 3 months.21 If minor stroke 
patients deteriorate and rescue MT is performed later (68% >8 
hours from onset), MT (n=28) seemed to be associated with 
better outcome (adjusted OR: 10.9; 95% CI [3–38]) compared 
with those without MT (n=181).22 However, rescue MT may be 
inferior to IMT in these patients. Haussen et al1 prospectively 
compared the impact of IMT (n=10) versus initial medical 
treatment (n=22, including rescue thrombectomy if clinical 
deterioration) on NIHSS difference from admission to dis-
charge. They found that patients with IMT had higher NIHSS 
improvement (−2.5 versus 0; P<0.01) and a nonsignificantly 
better clinical outcome at 90 days (mRS 0–2: 100% versus 
77%; P=0.15).1 A follow-up study from the same group with 
a larger sample size corroborated the aforementioned findings 
and but also demonstrated improved rates of independence 
at follow-up.17 Messer et al16 showed the same trend favor-
ing IMT; good outcomes (mRS, 0–2) were higher in patients 
with IMT (75%; n=8) as compared with patients with rescue 
MT (33%; n=6). Notably, patients from these cohorts were 
included in the current analysis. Conversely, Dargazanil et al14 
demonstrated that patients (n=301) with LVO and NIHSS <8 
achieved comparable excellent outcomes (mRS 0–1, 64.5%) 
but better perfect outcomes (mRS 0, 39.4% versus 27.5%; 
P=0.03) with IMT versus BMM, including rescue MT.23 In 
another analysis on 138 patients (NIHSS ≤8) who underwent 
MT, the reperfusion grade was significantly associated with 
an increase in excellent outcome; the OR (95% CI) was 3.09 
(1.06–9.03) for Thrombolysis in Cerebral Infarction 2B and 
6.66 (2.27–19.48) for Thrombolysis in Cerebral Infarction 3.24 
A study on 78 patients from Spain found no benefit for MT 
within 6 hours after onset over BMM but an increased risk for 
sICH after MT (11.8% versus 0%; P=0.033).15 In our analysis, 
as well as in all other above-mentioned series, no significant 
increase in sICH was observed, with low rates in both groups 
(5% versus 1.4%; P=0.08).
The healthcare impact of this condition is likely consid-
erable. Minor neurological deficits (NIHSS, 0–5) are very 
common representing approximately half of all strokes.25 
The LVO rates for patients with acute ischemic stroke vary 
according to clinical severity but are estimated to represent 
≈20% of all strokes, and up to 10% of all LVOs may occur 
with mild symptoms.26–28 In specialized centers with a high 
volume endovascular service, LVOs can be detected in up to 
30% in selected minor stroke patients.16 Moreover, a popu-
lation-based study suggests that there are as many patients 
with transient ischemic attack as patients with low NIHSS 
strokes29 and that their LVO rates are likely to be comparable.4 
However, because current guidelines only recommend MT in 
patients with NIHSS ≥6,30 acute vessel imaging in patients 
with milder symptoms is not routinely performed and hence 
many of these cases are missed.31 Therefore, the absolute rates 
of patients meeting the inclusion criteria for this analysis were 
low (2.1%–12.2%) in the contributing databases, but this is 
most likely because of the fact that only a minority of low 
NIHSS patients received acute vessel imaging.
Our study has significant limitations, most of which are 
inherent to its retrospective nature and noncontrolled design, 
including the potential for selection bias, as well as the heter-
ogeneous treatment approach across the different centers over 
Figure. Ninety-day modified Rankin Scale 
(mRS) distribution based on the matched co-
hort. BMM indicates best medical management; 
IMT, immediate mechanical thrombectomy; and 
MT, mechanical thrombectomy.
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time. As such, although we have done our best to adjust for 
potential confounders, our results should be interpreted with 
caution and viewed as exploratory and hypothesis generating. 
Only a prospective, randomized controlled trial can appropri-
ately address the critical question on optimal initial manage-
ment for LVO patients presenting with low clinical severity.
Conclusions
Our retrospective, pilot analysis suggests that immediate 
thrombectomy in LVO patients with low NIHSS on pre-
sentation may be safe and has the potential to result in 
improved outcomes. Randomized clinical trials are war-
ranted to establish the optimal management approach for 
this patient population.
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